All change at Valeant, as CEO ousted and CFO asked to leave

21 March 2016

Troubled Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) today announced that it has initiated a search for a new chief executive officer, appointed William Ackman, chief executive of hedge fund Pershing Square Management and a major shareholder (9% stake), to its board of directors, and provided an update on certain accounting and financial reporting matters.

Current long-time CEO Michael Pearson, who has been ousted, will continue to serve in this position and as a director until his replacement is appointed. The news pushed Valeant’s beleaguered shares up 8.7% at $29.32 mid-morning.

Robert Ingram, chairman of the board, stated: "While the past few months have been difficult, Valeant has a collection of leading brands, valuable franchises and great people, and I am confident that the company will be able to rebuild its reputation and thrive under new leadership.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK